Elicio Therapeutics, Inc. 8-K

What Happened

• Elicio Therapeutics, Inc. announced it entered into a Securities Purchase Agreement to sell 4,380,313 shares of common stock at $3.43 per share in a registered direct offering, generating approximately $15.0 million in gross proceeds. The Offering is expected to close on July 6, 2026, subject to customary closing conditions.
• The Offering is being conducted pursuant to the company’s Form S-3 registration statement declared effective March 16, 2026. Titan Partners Group (a division of American Capital Partners) is lead placement agent and B. Riley Securities is co-placement agent; placement agents’ fees and related offering expenses will be paid (amounts not specified). The Company also provided a legal opinion on the issuance.

Key Details

• Shares to be sold: 4,380,313 common shares.
• Offering price: $3.43 per share.
• Gross proceeds to Elicio: approximately $15.0 million (before placement agents’ fees and offering expenses).
• Expected closing date: July 6, 2026; 30-day restriction on issuance/sale of common stock or equivalents after closing.

Why It Matters

• This registered direct offering gives Elicio immediate capital—about $15M gross—to support its operations and development programs.
• Because the shares are being sold under a registration statement, the offering is subject to SEC registration rules and customary closing conditions.
• Investors should note potential dilution from the new shares and that placement agents will be paid fees and expenses (not quantified in the filing). The 30-day restriction limits further issuance or sales of stock or equivalents immediately after closing, which may temporarily reduce additional dilution risk.